D C Hammell1, L P Zhang2, F Ma2, S M Abshire2, S L McIlwrath2, A L Stinchcomb1, K N Westlund2. 1. Department of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, KY, 40536-0082, USA. 2. Department of Physiology, University of Kentucky College of Medicine, Lexington, KY, 40536-0298, USA.
Abstract
BACKGROUND: Current arthritis treatments often have side-effects attributable to active compounds as well as route of administration. Cannabidiol (CBD) attenuates inflammation and pain without side-effects, but CBD is hydrophobic and has poor oral bioavailability. Topical drug application avoids gastrointestinal administration, first pass metabolism, providing more constant plasma levels. METHODS: This study examined efficacy of transdermal CBD for reduction in inflammation and pain, assessing any adverse effects in a rat complete Freund's adjuvant-induced monoarthritic knee joint model. CBD gels (0.6, 3.1, 6.2 or 62.3 mg/day) were applied for 4 consecutive days after arthritis induction. Joint circumference and immune cell invasion in histological sections were measured to indicate level of inflammation. Paw withdrawal latency (PWL) in response to noxious heat stimulation determined nociceptive sensitization, and exploratory behaviour ascertained animal's activity level. RESULTS: Measurement of plasma CBD concentration provided by transdermal absorption revealed linearity with 0.6-6.2 mg/day doses. Transdermal CBD gel significantly reduced joint swelling, limb posture scores as a rating of spontaneous pain, immune cell infiltration and thickening of the synovial membrane in a dose-dependent manner. PWL recovered to near baseline level. Immunohistochemical analysis of spinal cord (CGRP, OX42) and dorsal root ganglia (TNFα) revealed dose-dependent reductions of pro-inflammatory biomarkers. Results showed 6.2 and 62 mg/day were effective doses. Exploratory behaviour was not altered by CBD indicating limited effect on higher brain function. CONCLUSIONS: These data indicate that topical CBD application has therapeutic potential for relief of arthritis pain-related behaviours and inflammation without evident side-effects.
BACKGROUND: Current arthritis treatments often have side-effects attributable to active compounds as well as route of administration. Cannabidiol (CBD) attenuates inflammation and pain without side-effects, but CBD is hydrophobic and has poor oral bioavailability. Topical drug application avoids gastrointestinal administration, first pass metabolism, providing more constant plasma levels. METHODS: This study examined efficacy of transdermal CBD for reduction in inflammation and pain, assessing any adverse effects in a rat complete Freund's adjuvant-induced monoarthritic knee joint model. CBD gels (0.6, 3.1, 6.2 or 62.3 mg/day) were applied for 4 consecutive days after arthritis induction. Joint circumference and immune cell invasion in histological sections were measured to indicate level of inflammation. Paw withdrawal latency (PWL) in response to noxious heat stimulation determined nociceptive sensitization, and exploratory behaviour ascertained animal's activity level. RESULTS: Measurement of plasma CBD concentration provided by transdermal absorption revealed linearity with 0.6-6.2 mg/day doses. Transdermal CBD gel significantly reduced joint swelling, limb posture scores as a rating of spontaneous pain, immune cell infiltration and thickening of the synovial membrane in a dose-dependent manner. PWL recovered to near baseline level. Immunohistochemical analysis of spinal cord (CGRP, OX42) and dorsal root ganglia (TNFα) revealed dose-dependent reductions of pro-inflammatory biomarkers. Results showed 6.2 and 62 mg/day were effective doses. Exploratory behaviour was not altered by CBD indicating limited effect on higher brain function. CONCLUSIONS: These data indicate that topical CBD application has therapeutic potential for relief of arthritis pain-related behaviours and inflammation without evident side-effects.
Authors: Richard Hastings; Tina Ding; Sayqa Butt; Kate Gadsby; Weiya Zhang; Robert J Moots; Chris Deighton Journal: Arthritis Care Res (Hoboken) Date: 2010-06 Impact factor: 4.794
Authors: Steve McGaraughty; Katharine L Chu; Richard J Perner; Stan Didomenico; Michael E Kort; Philip R Kym Journal: Mol Pain Date: 2010-03-05 Impact factor: 3.395
Authors: Malcolm Begg; Pál Pacher; Sándor Bátkai; Douglas Osei-Hyiaman; László Offertáler; Fong Ming Mo; Jie Liu; George Kunos Journal: Pharmacol Ther Date: 2005-01-11 Impact factor: 12.310
Authors: G Cunnane; L Bjork; A K Ulfgren; S Lindblad; O FitzGerald; B Bresnihan; U Andersson Journal: Ann Rheum Dis Date: 1999-08 Impact factor: 19.103
Authors: Lauren S Whyte; Erik Ryberg; Natalie A Sims; Susan A Ridge; Ken Mackie; Peter J Greasley; Ruth A Ross; Michael J Rogers Journal: Proc Natl Acad Sci U S A Date: 2009-09-03 Impact factor: 11.205
Authors: Mikhail Y Kochukov; Terry A McNearney; Huaizhi Yin; Liping Zhang; Fei Ma; Larissa Ponomareva; Sarah Abshire; Karin N Westlund Journal: Mol Pain Date: 2009-08-20 Impact factor: 3.395
Authors: Kevin F Boehnke; J Ryan Scott; Evangelos Litinas; Suzanne Sisley; David A Williams; Daniel J Clauw Journal: J Pain Date: 2019-09-24 Impact factor: 5.820
Authors: Stevie C Britch; Alan G Goodman; Jenny L Wiley; Abby M Pondelick; Rebecca M Craft Journal: J Pharmacol Exp Ther Date: 2020-03-16 Impact factor: 4.030
Authors: Brienna N Meffert; Danielle M Morabito; Michelle K Mosich; Mallory J Loflin; James Sottile; Adrienne J Heinz Journal: Curr Drug Res Rev Date: 2019